Skip to content
Triangle logo TriangleGet started
← Full study record

NCT06357975 · FLOW

Participant flow

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) · Source last updated 2026-03-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients receive crizotinib 250 mg PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    id
    FG000
    title
    Treatment (Crizotinib)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Ineligible or Never Started
    2. reasons
      1. group Id
        FG000
        num Subjects
        12
      type
      Mutation Status Not Confirmed
    3. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Adverse Event
    4. reasons
      1. group Id
        FG000
        num Subjects
        19
      type
      Disease Progression
    5. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Other Complicating Disease
    6. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Physician Decision
    7. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      On Treatment
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        44
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        40
      type
      Started Protocol Therapy
    3. achievements
      1. group Id
        FG000
        num Subjects
        28
      comment
      Primary efficacy analysis set
      type
      Eligible, Treated and Mutation Status Confirmed
    4. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    5. achievements
      1. group Id
        FG000
        num Subjects
        44
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
For subprotocol C1, patients were required to have MET amplification defined as ≥7 copies/cell as identified by the Oncomine® Assay, or the Oncomine® Assay equivalent of 7 or greater as identified by a Designated Laboratory.
recruitment Details
Subprotocol C1 was activated on May 31, 2016. Forty-four patients were enrolled on EAY131-C1 between July 29, 2016, and November 12, 2021. Thirteen patients were enrolled on the basis of the results from the NCI-MATCH assay and 31 on the basis of the outside assay results.
Complete source fields
groups
  1. description
    Patients receive crizotinib 250 mg PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    id
    FG000
    title
    Treatment (Crizotinib)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Ineligible or Never Started
    2. reasons
      1. group Id
        FG000
        num Subjects
        12
      type
      Mutation Status Not Confirmed
    3. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Adverse Event
    4. reasons
      1. group Id
        FG000
        num Subjects
        19
      type
      Disease Progression
    5. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Other Complicating Disease
    6. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Physician Decision
    7. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      On Treatment
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        44
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        40
      type
      Started Protocol Therapy
    3. achievements
      1. group Id
        FG000
        num Subjects
        28
      comment
      Primary efficacy analysis set
      type
      Eligible, Treated and Mutation Status Confirmed
    4. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    5. achievements
      1. group Id
        FG000
        num Subjects
        44
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
For subprotocol C1, patients were required to have MET amplification defined as ≥7 copies/cell as identified by the Oncomine® Assay, or the Oncomine® Assay equivalent of 7 or greater as identified by a Designated Laboratory.
recruitment Details
Subprotocol C1 was activated on May 31, 2016. Forty-four patients were enrolled on EAY131-C1 between July 29, 2016, and November 12, 2021. Thirteen patients were enrolled on the basis of the results from the NCI-MATCH assay and 31 on the basis of the outside assay results.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice